Experts’ views on developments in EGFR+ NSCLC from June 2021

Learning objective:         

After watching this broadcast, participants should be able to:

• Describe the novel treatment paradigms for patients with EGFR mutations with advanced NSCLC
• Evaluate the impact of latest advances in the clinical landscape for NSCLC EGFR exon 20 insertion mutations

Co-chairs:

• Matthew Krebs (UK)
• Antonio Passaro (Italy)

Faculty:

• Frank Griesinger (Germany)
• David Planchard (France)

This educational activity has been awarded 2 CPD points by CPDUK, a globally recognised provider of CPD.